Innovent says IBI3003 posts 84.6% ORR at Phase 1 RP2D in relapsed multiple myeloma
Innovent reported updated Phase 1 results for IBI3003 at RP2D at the 2026 IMS meeting, including an 84.6% ORR. Management said data supported Phase 2 dose selection and described rapid, deep and durable responses in heavily pretreated patients, with manageable safety and immune-related events largely low-grade.